Koers MustGrow Biologics Corp. Canadian Securities Exchange
Aandelen
MGRO
CA62822A1030
Biotechnologie & Medisch Onderzoek
Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
- CAD | -.--% | +6,74% | -28,57% |
Omzet 2023 * | - | Omzet 2024 * | - | Marktkapitalisatie | 54,22 mln. 39,59 mln. 37,07 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2023 * | - | Nettowinst (verlies) 2024 * | - | EV/omzet 2023 * | - |
Nettoliquiditeiten 2023 * | - 0 0 | Nettoliquiditeiten 2024 * | - 0 0 | EV/omzet 2024 * | - |
K/w-verhouding 2023 * |
-11,7
x | K/w-verhouding 2024 * |
-
| Werknemers | - |
Dividendrendement 2023 * |
-
| Dividendrendement 2024 * |
-
| Vrij verhandelbaar | 88,6% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Corey Giasson
CEO | Chief Executive Officer | 46 | 15-03-18 |
Todd Lahti
DFI | Director of Finance/CFO | 58 | 17-12-18 |
Colin Bletsky
COO | Chief Operating Officer | 49 | 15-03-18 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Brian Quigley
BRD | Director/Board Member | 50 | 17-07-19 |
Brad Munro
CHM | Chairman | 64 | 15-03-18 |
Corey Giasson
CEO | Chief Executive Officer | 46 | 15-03-18 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-0,02% | 42,11 mld. | |
+46,34% | 40,08 mld. | |
+5,04% | 40 mld. | |
-11,32% | 26,87 mld. | |
+5,25% | 24,58 mld. | |
-23,83% | 18,44 mld. | |
-1,62% | 11,94 mld. | |
+22,75% | 11,66 mld. | |
+6,44% | 11,01 mld. |
- Beurs
- Aandelen
- Koers MGRO
- Koers MGRO